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Kinetic study of adenosine concentrations and the expression of
adenosine deaminase in mononuclear cells during hemodialysis.
Background. We previously showed that high intralympho-
cytic adenosine (Ado) concentrations are found in hemodi-
alyzed patients due to the reduced activity of mononuclear
cell adenosine deaminase (MCADA). These abnormalities con-
tribute to the immune defect observed in HD patients. The ki-
netics of these abnormalities and the causes of the low MCADA
activity, however, have not been investigated. Here, we ad-
dressed this question. Since interferon gamma (IFNc) partially
modulates MCADA, we also evaluated the effect of IFNc on
MCADA activity in vitro.
Methods and Results. The study included 12 patients (eight
men and four women) who were observed from the first to
the 36th hemodialysis (HD) session, and eight healthy sub-
jects (controls). MCADA activity and Ado concentrations
were normal before the first HD session. Ado concentrations
progressively increased from the first (10.5 ± 3.1 pmol/107
cells) to the fourth session (26.7 ± 3 pmol/107 cells), before
stabilizing at a high level. MCADA activity increased tran-
siently until the second session (2.2 ± 0.5 IU/107 cells before
HD vs. 2.8 ± 0.6 IU/107cells), and then decreased and sta-
bilized at a low level (1.0 ± 0.5 IU/107cells). The amount of
MCADA mRNA transiently increased until the third session
(mRNA MCADA/mRNA b-actin: 0.6 ± 0.2 vs. 0.8 ± 0.2), and
then decreased to 0.3 ± 0.1 at the 36th session. MCADA activity
underwent a dose-dependent increase after IFNc stimulation.
Conclusion. HD affects the transcription of the gene encod-
ing MCADA after just three HD sessions, leading to decreased
MCADA activity and increased plasma concentration of Ado.
Adenosine (Ado) is a ubiquitous nucleoside that par-
ticipates in a large number of physiologic processes
[1, 2]. The metabolism of Ado has been studied in healthy
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subjects and in patients with cardiac, neurologic, and
renal diseases [1, 3–6]. Ado is released into the extra-
cellular compartment by endothelial cells and by sev-
eral tissues, particularly in response to hypoxia [1]. Ado,
which acts on purinergic receptors, has vasodilatory prop-
erties and exerts a strong immunosuppressive effect
by inhibiting the ribonucleotide reductase of lympho-
cytes [7]. The Ado found in mononuclear cells is either
formed by the hydrolysis of nucleotides or is taken up
from the extracellular medium via a facilitated diffusion
transport system [8] and via a concentrative transport
system [9]. Ado is rapidly deaminated to inosine by
adenosine deaminase (ADA) (Fig. 1). This ubiquitous en-
zyme is found in large quantities, particularly in mononu-
clear cells (MCADA for mononuclear cell adenosine
deaminase).
Hemodialysis (HD) patients have high concentrations
of Ado both in serum and in mononuclear cells due to a
decrease in MCADA activity [6, 10]. The uptake of Ado
by red blood cells, blood ADA activity, and mononuclear
cell Ado kinase activity are all normal in HD patients,
suggesting that no other metabolic pathways are altered
[6, 10]. In contrast to HD patients, chronic renal failure
patients and those treated by peritoneal dialysis have nor-
mal Ado metabolism, suggesting that its abnormalities
are induced by HD [6].
We previously showed that high Ado concentrations
and low MCADA activity are involved in the dialysis-
induced immunodeficiency in HD patients [6, 10]. Indeed,
Ado and its metabolites deteriorate lymphocyte function
and proliferation in a dose-dependent manner [10], and
low MCADA activity not only increases the intracellular
Ado concentration [6, 10–12] but also inactivates T cells
by interacting with CD26 [13].
HD also decreases cytokine production [14]. Some
authors have reported that activated mononuclear cells
from HD patients produce only low levels of interferonc
(IFNc( [10, 15], and there is a link between MCADA and
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Fig. 1. Metabolism of adenosine (Ado) and metabolites. Ado is
formed in endothelial cells from the hydrolysis of nucleotides via a 5′-
nucleotidase. Most Ado is released into the extracellular spaces, where
its binds to purinergic receptors of target cells, causing smooth muscle
relaxation and vasodilation. Ado is quickly taken up by blood cells. The
part of nucleosides that have not been taken up is quickly deaminated to
inosine via extracellular adenosine deaminase (ADA). The final prod-
uct of Ado metabolism is uric acid with production of H2O2. ADA is
also found in large quantities in red blood cells and mononuclear cells
(MCADA), where it regulates both the intra- and extracellular adeno-
sine concentration.
IFNc, since IFNc partially modulates ADA activity [16,
17].
The aim of this study was to assess the kinetics of
Ado and MCADA changes in patients beginning an HD
program. In addition, we investigated the effect of HD
on MCADA mRNA levels and the effect of IFNc on
MCADA activity in vitro.
METHODS
Patients
This study included 12 consecutive patients (eight men
and four women) with end-stage renal failure (ESRF) be-
ginning an HD program. Patients who had been treated
with papaverine, dipyridamole, or immunosuppressive
agents during the previous six months were excluded
from the study. Patients (mean age ± SD was 59.6 ±
19.4 years; range 30 to 86 years) were included on the
day they started HD. Causes of ESRF were diabetic
nephropathy (N = 1), chronic glomerulonephritis (N =
1), interstitial nephritis (N = 2), polycystic kidney dis-
ease (N = 4), nephroangiosclerosis (N = 2), and unde-
termined (N = 2). None of the patients had human im-
munodeficiency virus (HIV), hepatitis B (HBV), or hep-
atitis C (HCV) infections. The characteristics of the HD
sessions were the same for all the patients: three times a
week for 5 ± 1 hour with high permeability cellulose diac-
etate and triacetate membranes (DICEA 110, DIOCEA
150, TRICEA 110, TRICEA 190; Baxter Healthcare Cor-
poration, McGaw Park, IL, USA). The hemodialyzers
were not reused. The composition of the dialysate was
140 mmol/L sodium, 2 mmol/L potassium, 1.75 mmol/L
calcium, 32 mmol/L bicarbonate, 4 mmol/L acetate. Vas-
cular access was either a native radial arteriovenous fis-
tula (N = 11) or a polytetrafluorethylene (PTFE) graft
fistula (N = 1). An endotoxin-free, nonpyrogenic ultra-
pure bicarbonate dialysate was used. Dialysis water was
tested every week with the Limulus amoebocyte lysate
assay. Endotoxin counts were lower than 0.01 endotoxin
U/mL. The blood and dialysate flow rates were 250 and
500 mL/min, respectively. Mean hemoglobin concentra-
tion was 10.4 ± 0.9 g/100 mL, and mean hematocrit was
33 ± 4%. Seven patients were receiving recombinant hu-
man erythropoietin (9000 ± 3500 IU/week). Before the
first HD session, the mean serum creatinine level was
706 lmol/L and blood urea nitrogen (BUN) was
53 mmol/L. The mean Kt/V was 1.6 ± 0.43 (range 1 to
2.2). The mean CD3+ cell count was 959 ± 120. Control
subjects were healthy volunteers (N = 8: 4 women and 4
men, mean age 48 ± 24 years, range 30 to 61) without any
medication. All participants gave their consent in accor-
dance with the Helsinki convention, and the study was
approved by the local ethics committee.
Methods
Reagents. Ado (crystallized, 99% pure), dipyra-
midole, a,b methylene-adenosine-5′-diphosphate
(AOPCP), 9-erythro (2-hydroxy−3-nonyl) adenine
(EHNA), L-phytohemagglutinin (PHA), and Na2-
Ethylenediaminetetracetic acid (Na2-EDTA) were from
Sigma (Saint-Quentin Fallavier, France). Deoxyco-
formycin (dcf) was from Lederle Laboratories (Paris,
France). Heparin was from Sanofi Winthrop (Gentilly,
France). Bovine serum albumin (BSA) was from Johnson
and Johnson Clinical Chemistry (Rochester, NY, USA).
RPMI 1640 was from BioWhittaker (Emerainville,
France). The reversed phase chromatography column
(Merck LIChrospher C18, and RP8 250 × 4 mm) and
other reagents were from Merck (Darmstadt, Germany).
Blood samples for intramononuclear cell Ado
measurements
Patients and controls were asked not to drink coffee
or tea for 72 hours before blood samples were taken.
Samples were collected before the first four HD sessions
and before the 12th and 36th HD session. Samples were
collected as previously described [6, 10]. Briefly, blood
from the brachial vein (8 mL/sample) was drawn into
vacuum tubes containing a stopping solution (0.2 mmol/L
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dipyridamole, 4.2 mmol/L Na2 EDTA, 5 mmol/L EHNA,
79 mmol/L AOPCP, 1 IU/mL heparin sulfate, 200 lg/mL
deoxycoformycin, and 0.9% NaCl) to prevent the degra-
dation and uptake of Ado. The samples were transferred
to Vacutainer tubes (Ficoll-based CPT system; Becton
Dickinson, Franklin Lakes, NJ, USA) and centrifuged
(500g, 30 minutes). A 1 mL sample of interphase cells
was then collected and washed three times with 3 mL
of the stopping solution before assessing cell viability
by the trypan blue dye exclusion test. Granulocyte con-
tamination and the number of mononuclear cells were
measured (Beckman Coulter Epics XL, Fullerton, CA,
USA). These techniques resulted in cell preparations that
were >98% viable and that contained less than 3% of
granulocytes. The proportion of lymphocytes always ex-
ceeded 95%. Cells were resuspended in stopping solu-
tion (5.9 ± 1.5 × 106 cell/mL) and frozen (−80◦C). Sam-
ples were subjected to four freeze-thaw cycles (−80◦C,
+37◦C) and centrifuged (2500g, 10 minutes) to obtain
clear supernatant cell extracts. Supernatants were depro-
teinized with 100 lL of perchloric acid (6N) and cen-
trifuged (1500g, 10 minutes). Samples were lyophilized
before chromatography.
Blood samples for MCADA measurements
Samples (8 mL) of whole blood were collected from
all patients and controls in Vacutainer tubes (CPT Sys-
tem, Becton Dickinson), and centrifuged for 30 minutes.
A 1-mL sample of interphase cells (6.3 ± 1 × 106) was
washed four times with 3 mL of 0.9% NaCl to eliminate
plasma ADA. One-mL aliquots were submitted to four
freeze-thaw cycles before centrifugation (2500g, 10 min-
utes) to obtain clear supernatant cell extracts. The cell
extracts were assayed for ADA levels.
MCADA activity
MCADA activity was measured as previously de-
scribed [6, 10]. Briefly, 750 lL of 28 mmol/L Ado was
mixed with 125 lL of the cell extract and 125 lL of 7%
BSA in 0.9% NaCl. Aliquots were then incubated for
1 hour at 37◦C. The reaction was started by adding the
substrate, and was stopped by cold immersion (4◦C). The
Johnson and Johnson Clinical Chemistry (Rochester,
NY, USA) colorimeter test was used to determine ammo-
nia concentrations. The intra- and interassay coefficients
of variation ranged from 3% to 5%.
Mononuclear cell culture
Cells were collected from patients before the 36th HD
session, as described above. One mL of interphase cells,
prepared as described above, was washed three times in
phosphate-buffered saline (PBS) buffer and resuspended
in RPMI 1640 before counting cells and assessing viabil-
ity. Cells were cultured for 72 hours in the presence of
5 lg/mL of PHA and 10, 100, or 1000 pg/mL of IFNc.
MCADA activity was evaluated as described above.
Ado assay
The technique was carried out as described previ-
ously [18]. A Hewlett Packard HP 1100 modular sys-
tem with a diode array detector was used (Hewlett
Packard, Palo Alto, CA, USA). Lyophilized samples
(500 lL) were mixed with 1 mL of phosphate buffer
(NaH2PO4/Na2HPO4, pH 4), injected into a 1-mL loop,
and then eluted with a methanol gradient on a Merck
LIChrospher C18 column (0% for 3 minutes, then 10%
to 25% methanol over 15 minutes). The intra- and in-
terassay coefficients of variation for nucleosides ranged
from 1% to 3%. The detection limit at 254 nm was
1 pmol/mL. Retention times and spectra were compared
to those of exogenous adenosine and metabolites. Quan-
tifications were determined by comparing areas obtained
for samples with areas of known quantities of nucleosides.
RNA extraction
Total cellular RNA was extracted from mononuclear
cells by the acid guanidinium thiocyanate phenol chlo-
roform method. The reagent used was Trizol LS (Life
Technologies, Gaithersburg, MD, USA).
Reverse transcriptase polymerase chain reaction
(RT-PCR)
Total RNA (0.5 lg) was reverse transcribed in the pres-
ence of random hexamers by use of M-MLV reverse
transcriptase (Pharmacia Biotech, Inc., Orsay, France)
according to the manufacturer’s recommendations. The
resulting cDNA (2 lL) was polymerase chain reac-
tion (PCR) amplified with primers derived from ADA
cDNA sequences (accession number NM 13792). The se-
quences of the ADA primers were: ADA sense 5′ GGT-
GTA TGT GGAGGTGCGGCGGTACA, 3′ and ADA
antisense 5′ TCCACAGCCTCTTTT ACTACTTCG 3′.
These primers were designed to generate a 440-bp PCR
product. The sequences of the b-actin–specific primers
were: sense 5′ TTGTAACCAACTGGGACGATATGG
3′ and antisense 5′ GATCTTGATCTTCATGGTGCT-
TAGG 3′. These primers were designed to generate an
838-bp PCR product, serving as an internal standard.
PCR was performed on a Perkin-Elmer thermocycler
9600 (Perkin-Elmer, Boston, MA, USA), with 28 cycles
at 94◦C for 15 seconds, 58◦C for 30 seconds, and 72◦C for
30 seconds, and then a simple extension step at 72◦C for
3 minutes. After PCR, a 10 lL aliquot of each sample
was subjected to electrophoresis on a 2% agarose gel, and
the PCR product was stained with ethidium bromide and
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Fig. 2. Analysis of mononuclear cell adenosine deaminase (MCADA)-
and b-actin–related polymerase chain reaction (PCR) products. Total
cellular RNA was extracted from mononuclear cells collected from a
hemodialyzed patient (1 among 12) before the first four HD sessions,
and before the 12th and 36th HD sessions. RNA was reverse transcribed,
and the resulting cDNA was PCR amplified with primers derived from
ADA cDNA sequences and with b-actin–specific primers (internal stan-
dard). Each sample was subjected to electrophoresis on a 2% agarose
gel and the PCR products were stained with ethidium bromide and
viewed on a UV illuminator. Gels were digitized (left). Relationship
between signal intensity and cycle number (25, 35, or 38 cycles; right).
viewed on an ultraviolet (UV) illuminator. PCR products
were verified by sequence analysis.
Relative RT-PCR to determine the MCADA mRNA
concentration
To compensate for variations in RNA isolation and for
tube-to-tube variations in RT-PCRs and PCRs, relative
RT-PCR was carried out using b-actin as an internal stan-
dard. To increase reproducibility, the concentration of the
PCR product was adjusted relative to that of the coampli-
fied internal standard. The target and b-actin PCR prod-
ucts were analyzed during the linear amplification stage
of PCR. Gels were digitized and analyzed with NIH im-
age 6.1 and Molecular Analyst (Bio-Rad, Hercules, CA,
USA) software. MCADA activity is expressed in inter-
national units (IU) per 106 cells.
Statistical analysis
The Wilcoxon test was used for intragroup comparisons
(Ado concentration, MCADA activity, and mRNA level
as a function of HD session number in the same group).
A two-way analysis of variance (ANOVA) was used for
MCADA levels as a function of INFc concentration. A
value of P less than 0.05 was considered significant.
RESULTS
Intramononuclear cell Ado concentration
The intramononuclear cell Ado concentration was nor-
mal before the first HD session (patients vs. controls:
10.5 ± 3.1 vs. 12 ± 4 pmol/107 cells, P > 0.05). The Ado
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Fig. 3. Effect of the hemodialysis sessions on intramononuclear cell
Ado concentrations, MCADA activity (IU for international unit), and
MCADA mRNA levels. MCADA mRNA levels are expressed relative
to those of b-actin mRNA. Samples from patients (N = 12) were col-
lected before the first four hemodialysis sessions (HD session 1 to HD
session 4), and before the 12th and 36th sessions (HD session 12 and
HD session 36). Controls are in white. ∗Wilcoxon test, P < 0.05 com-
pared with HD session 1. ∗∗Wilcoxon test, P > 0.005 compared with
HD session 12.
concentration steadily increased from HD session 1 to
HD session 4 (10.5 ± 3.1 vs. 26.7 ± 3; mean change vs.
HD session 1: +154%, P < 0.01). After HD session 4,
the Ado concentration stabilized at a high level (Fig. 2).
No significant difference was found regarding Ado con-
centration between HD session 4 and HD session 36
(Fig. 3).
MCADA activity
Before the first HD session, MCADA activity was nor-
mal (patients vs. controls 2.2 ± 0.5 vs. 2.1 ± 0.4 IU; P >
0.05). MCADA activity increased significantly from HD
session 1 to HD session 2 (2.2 ± 0.5 vs. 2.8 ± 0.6 IU; mean
change vs. HD session 1: +27%, P < 0.05), and then de-
creased between HD session 2 and HD session 3 (1.6 ±
0.4 IU; mean change vs. HD session 1: −27%, P < 0.01).
MCADA activity stabilized at HD session 12 (1 ± 0.5 IU;
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Fig. 4. Effects of increasing doses of interferon-c (INFc) on mononu-
clear cells adenosine deaminase (MCADA) activity in patients (N = 12)
and in controls (N = 8). ∗P < 0.05 compared with controls. ∗∗P > 0.05
compared with 100 pg of INFc.
mean change vs. HD session 1: −55%) with no significant
variation afterwards (Fig. 3).
MCADA mRNA levels
Before the first HD session, MCADA mRNA was nor-
mal (patients vs. controls; mRNA MCADA/mRNA b-
actin, 0.6 ± 0.2 vs. 0.5 ± 0.1; P > 0.05). The concentration
of MCADA mRNA increased significantly from HD ses-
sion 1 to HD session 3 (0.6 ± 0.2 vs. 0.8 ± 0.2; mean
change vs. HD session 1: +38%, P < 0.05). The amount
of MCADA mRNA steadily decreased between HD ses-
sion 3 and HD session 36 (0.3 ± 0.1; mean change vs. HD
session 1: –53%, P < 0.01). No significant difference was
found in mRNA level from HD session 12 to HD session
36 (Fig. 3).
Effect of INFc on MCADA activity
In basal conditions, MCADA activity was significantly
lower in cells cultured in the absence of IFNc following
isolation from HD patients than in their control counter-
parts (0.8 ± 0.3 IU/106 cells vs. 1.5 ± 0.3 IU, P < 0.05).
After stimulation of the cells with 10 pg of INFc, MCADA
activity increased 1.6-fold in both patients and controls.
After stimulation with 100 pg of INFc, MCADA activity
increased 4.6-fold in patients, and by 4.3-fold in controls.
In the presence of higher IFNc concentrations, MCADA
activity plateaued both for patients and controls (P >
0.05, between 100 and 1000 pg) (Fig. 4).
DISCUSSION
It has been reported that HD induces mononuclear
cell apoptosis [19] through a mechanism not yet eluci-
dated, but which seems to involve both uremic serum
factors and dialysis membranes [20]. The immune de-
fect observed during HD is also associated with various
mononuclear cell dysfunctions. Most are related to re-
duced cytokine production by lymphocytes and mono-
cytes, especially natural killer [15], lymphokine-activated
killer [14], and T-helper 1 and 2 [21] cells. Finally, in addi-
tion to cytokine changes, various humoral factors, some of
which may still be unknown, are likely to be involved in
HD-related immunodeficiency. Ado, a potent immuno-
suppressive agent, is one of them.
We previously showed that HD patients have high
Ado levels in their plasma and mononuclear cells, re-
lated to low MCADA activity. Conversely, Ado levels and
MCADA activity are within the normal range in undia-
lyzed chronic renal failure patients and in ESRF patients
treated by peritoneal dialysis [6, 10]. However, the kinet-
ics of alterations in Ado levels and in MCADA activity
after the beginning of HD were unknown.
We found here that intramononuclear cell Ado concen-
trations increased rapidly after the onset of HD and re-
mained stable at a significantly high level from the fourth
session onward. We previously demonstrated that this in-
crease is due to a decrease in MCADA activity, as shown
by the negative correlation between Ado and MCADA
[6, 10]. The current results are consistent with this corre-
lation, since MCADA activity, after a transient increase,
decreased, whereas Ado levels increased as soon as HD
was started.
We also explain here the decrease in MCADA activity
since we demonstrated that the transcription of the gene
encoding this enzyme is defective: MCADA mRNA lev-
els decreased regularly from the fourth session onward,
until they reached about 50% of their initial value.
The regulation of ADA gene expression is poorly
understood. It is usually considered that the ADA gene
is a housekeeping gene. Tissue-specific expression of the
human ADA gene, however, is mediated by transcrip-
tional activation over a several 100-fold range depending
on the tissue, ADA activity being highest in erythrocytes
and T cells [22]. ADA gene expression is regulated by
steroids since dexamethasone increases the quantity of
ADA mRNA [23]. It has been also reported that (1)
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ADA expressed by primary cell cultures or by cell lines
is partly induced by IFNc [16, 17, 24], (2) plasma ADA
activity is related to the number of IFNc-secreting cells
[25], and (3) HD is associated with multiple cytokine al-
terations, especially regarding IFNc production [10, 15,
26]. Because we [10] and others [26, 27] reported in HD
patients low secretion of IFNc by activated lymphocytes,
the sole source of IFNc production [28], we postulate that
mononuclear cells are chronically exposed to a low con-
centration of IFNc in HD patients, which may participate
in MCADA biosynthesis changes observed in the present
study. Finally, the increase of Ado in blood may partici-
pate in the high level of H2O2 observed in HD patients,
Ado being converted in inosine and then to hypoxan-
thine, xanthine, and H2O2 through a xanthine oxidase
(Fig. 1). Thus, the question regarding the oxidative regu-
lation of the MCADA gene expression arises: What are
the consequences of these nucleoside abnormalities in
HD patients?
Deoxyadenosine and deoxyadenosine triphosphates
(dATP) accumulate in T-cells exposed to high Ado con-
centrations in a medium with low MCADA activity. These
nucleosides allosterically inhibit ribonucleotide reduc-
tases, and thus, inhibit DNA synthesis [29, 30]. Further-
more, the mononuclear cells of HD patients are more
sensitive to the toxicity of Ado and its derivatives due to
their low MCADA activity [10].
The decrease in MCADA activity has several implica-
tions: (1) MCADA is involved in the regulation of in-
tracellular and extracellular Ado concentrations [11, 12],
and the low MCADA activity participates in the progres-
sive increase of the Ado concentration in mononuclear
cells; (2) MCADA is implicated in T-cell activation via
noncovalent binding to the T-cell antigen CD26 [31]; (3)
normal MCADA activity is necessary for lymphocyte dif-
ferentiation and activity [32]. A vicious circle is likely to
occur in HD patients because Ado inhibits cell prolifera-
tion and IFNc production [10], and low IFNc concentra-
tions decrease MCADA activity.
The respective roles of the extra-body circulation,
the dialysis membrane, and the dialysate in nucleoside
metabolism abnormalities remain to be determined. The
former is not the culprit because open-heart surgery
does not alter Ado plasma concentrations (unpublished
data). Peritoneal dialysis patients have no nucleoside
abnormalities [6], and so dialysis membranes are more
likely to be involved in the defect than the dialysate.
Dialysis membranes, and more particularly bioincom-
patible membranes, induce cytokine alterations such as
decreased IFNc production in vitro [33].
CONCLUSION
We have found that HD sessions decrease MCADA
biosynthesis and activity, and increase the concentration
of Ado in mononuclear cells soon after the onset of the
HD process. Both of these events contribute synergisti-
cally to the HD-induced immune defect. Based on our
data in vitro and published findings, we also propose that
the low IFNc production in HD patients participates in
the decrease of MCADA expression. We are now inves-
tigating the respective roles of the membrane and the
dialysate in the transcriptional decrease of MCADA ac-
tivity. Furthermore, because inhibition of MCADA may
be considered as a new marker of biocompatibility, we
are investigating the effect of different types of dialysis
membranes on MCADA activity.
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